Ser391

Site Information
RLQQPRLsLQGHPtD SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4172650
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 8 , 9 , 10 , 11 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 )
Disease tissue studied:	breast cancer ( 4 , 10 ) , breast ductal carcinoma ( 4 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 4 ) , cervical cancer ( 19 ) , cervical adenocarcinoma ( 19 ) , lung cancer ( 10 , 17 ) , non-small cell lung cancer ( 8 , 10 ) , ovarian cancer ( 4 )
Relevant cell line - cell type - tissue:	293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 18 ) , breast ( 1 , 4 ) , BT-20 (breast cell) ( 10 ) , BT-549 (breast cell) ( 10 ) , Calu 6 (pulmonary) ( 10 ) , CL1-0 (pulmonary) ( 17 ) , CL1-1 (pulmonary) ( 17 ) , CL1-2 (pulmonary) ( 17 ) , CL1-5 (pulmonary) ( 17 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 11 ) , Flp-In T-Rex-293 (epithelial) ( 11 ) , H2009 (pulmonary) ( 10 ) , H2077 (pulmonary) ( 10 ) , H2887 (pulmonary) ( 10 ) , H322M (pulmonary) ( 10 ) , HCC1359 (pulmonary) ( 10 ) , HCC1937 (breast cell) ( 10 ) , HCC2279 (pulmonary) ( 10 ) , HCC366 (pulmonary) ( 10 ) , HCC4006 (pulmonary) ( 10 ) , HCC78 (pulmonary) ( 10 ) , HCC827 (pulmonary) ( 10 ) , HeLa (cervical) ( 3 , 9 , 16 , 20 , 21 , 22 ) , HeLa S3 (cervical) ( 19 ) , HOP62 (pulmonary) ( 10 ) , Jurkat (T lymphocyte) ( 6 , 13 , 15 ) , K562 (erythroid) ( 9 ) , LCLC-103H (pulmonary) ( 10 ) , liver ( 5 ) , MCF-7 (breast cell) ( 10 ) , MDA-MB-231 (breast cell) ( 10 ) , MDA-MB-468 (breast cell) ( 10 ) , NCI-H157 (pulmonary) ( 10 ) , NCI-H1648 (pulmonary) ( 10 ) , NCI-H1666 (pulmonary) ( 10 ) , NCI-H2172 (pulmonary) ( 10 ) , NCI-H3122 (pulmonary) ( 8 ) , NCI-H322 (pulmonary) ( 10 ) , ovary ( 4 )

Upstream Regulation
Treatments:	BI2536 ( 16 ) , ischemia ( 4 ) , nocodazole ( 19 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
3	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
4	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
5	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
6	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
7	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
8	Rikova K (2013) CST Curation Set: 18459; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC) Curated Info
9	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
10	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
11	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
12	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
13	Guo A (2012) CST Curation Set: 13981; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
14	Rikova K (2012) CST Curation Set: 13734; Year: 2012; Biosample/Treatment: cell line, Mix of TMT treated cell lines 3/treated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
15	Guo A (2011) CST Curation Set: 11890; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Curated Info
16	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
17	Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97 20815410 Curated Info
18	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
19	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
20	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
21	Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8 19276368 Curated Info
22	Cantin GT, et al. (2008) Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res 7, 1346-51 18220336 Curated Info